Target intelligence / Profile preview

Prothymosin alpha pseudogene 3 (PTMAP3)

Target
PTMAP3
Molecular classification
Pseudogene
01

Overview

Prothymosin alpha pseudogene 3 (PTMAP3) is a processed human pseudogene related to the prothymosin alpha gene (PTMA). Unlike the functional PTMA gene, PTMAP3 does not encode a functional protein. While members of the prothymosin alpha family play roles in cell proliferation and immunity, PTMAP3 and other pseudogenes in this family do not produce mRNA or protein products in human tissues and have no known biological or disease associations.

Other names
PTMAP3prothymosin, alpha pseudogene 3
02

Mechanism of action

null

Beyond the preview

Go deeper on Prothymosin alpha pseudogene 3 (PTMAP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prothymosin alpha pseudogene 3 (PTMAP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call